PEGINTRON
Biological
Merck Sharp & Dohme Corporation
Total Payments
$525,754
Transactions
18
Doctors
4
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $35,078 | 1 | 0 |
| 2021 | $117,543 | 2 | 0 |
| 2020 | $21,553 | 1 | 0 |
| 2019 | $51,139 | 2 | 0 |
| 2017 | $300,441 | 12 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $525,354 | 14 | 99.9% |
| Consulting Fee | $400.00 | 4 | 0.1% |
Payments by Type
Research
$525,354
14 transactions
General
$400.00
4 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase Ib Study of Yervoy with Sylatron for Patients with Unresectable Stages IIIB,C,IV Melanoma | Merck Sharp & Dohme Corporation | $126,837 | 0 |
| An Observational Pilot Study to Compare the Compliance with and Health Related Quality of Life during Therapy with Standard High-Dose Interferon Alfa Intron A, HDI versus Pegylated Alfa-Interferon 2b Sylatron , PEG IFN in Patients with Surgically Resected Melanoma | Merck Sharp & Dohme Corporation | $125,100 | 0 |
| An Observational Pilot Study to Compare the Compliance with and Health Related Quality of Life during Therapy with Standard High-Dose Interferon Alfa Intron A, HDI versus Pegylated Alfa-Interferon 2b Sylatron , PEG IFN in Patients with Surgically Resected Melanoma | Merck Sharp & Dohme LLC | $97,578 | 0 |
| Pilot Analysis of the Effects of IFN a2b upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients with and without Tumor-Involved Sentinel Lymph Nodes | Merck Sharp & Dohme Corporation | $55,043 | 0 |
| The Pathogenesis of Hepatitis C Virus Vertical Transmission | Merck Sharp & Dohme Corporation | $51,139 | 0 |
| A Phase II Trial of Peginterferon alfa-2b PEG-Intron for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas | Merck Sharp & Dohme Corporation | $45,250 | 0 |
| Phase II study of pegylated interferon -2b for pediatric patients with unresectable or recurrent craniopharyngioma | Merck Sharp & Dohme Corporation | $23,183 | 0 |
| Patients' and Primary Care Providers' Attitudes and Beliefs about Hepatitis C virus HCV and Treatment | Merck Sharp & Dohme Corporation | $1,224 | 0 |
Top Doctors Receiving Payments for PEGINTRON
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $427,776
- Merck Sharp & Dohme LLC $97,578
- COMSORT, Inc $400.00
Product Information
- Type Biological
- Total Payments $525,754
- Total Doctors 4
- Transactions 18
About PEGINTRON
PEGINTRON is a biological associated with $525,754 in payments to 4 healthcare providers, recorded across 18 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2023. In 2023, $35,078 was paid across 1 transactions to 0 doctors.
The most common payment nature for PEGINTRON is "Unspecified" ($525,354, 99.9% of total).
PEGINTRON is associated with 8 research studies, including "A Phase Ib Study of Yervoy with Sylatron for Patients with Unresectable Stages IIIB,C,IV Melanoma" ($126,837).